Nyrada (ASX:NYR) Other Income (Expense) : A$2.97 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Other Income (Expense)?

Nyrada's other income expense for the Nyrada's pretax income for the six months ended in Dec. 2023 was A$2.46 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.97 Mil.

Nyrada Other Income (Expense) Historical Data

The historical data trend for Nyrada's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Other Income (Expense) Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Other Income (Expense)

1.13

2.34

1.09

1.43

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial			-	1.09	1.07	0.51	2.46

Nyrada Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.97 Mil.

Nyrada (ASX:NYR) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines